The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to ... multiple-dose vial, making it readily accessible ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...

Merilog (insulin-aspart-szjj) is the first rapid-acting insulin ... a 3 mL single-use self-administered prefilled pen and a 10 mL multiple-dose vial. Patients administer the prefilled pen via ...

Insulin aspart is delivered by a subcutaneous shot ... Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

with a targeted price cap of $30 per vial and $55 per box of five prefilled pens. Recently, the company announced a partnership with Biocon Biologics to expand access to insulin aspart, a rapid-acting ...

Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj ... use prefilled pen and a 10-mL multiple-dose vial are included in this approval.

The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. Merilog is a ...